Cipla announced its unaudited consolidated financial results for the quarter ended September 30, 2021. In India, the overall business grew by 16 per cent YoY on a high FY21 base led by sustained volume traction across core therapies; covid portfolio contribution normalising in-line
with expectations.

Income from operations has been registered at Rs 5,520 crore, up by 10 per cent YoY. EBITDA has been posted at Rs 1,226 crore up by 4 per cent YoY and profit after tax at Rs 711 crore registering 7 per cent YoY.

Umang Vohra, MD and Global CEO, Cipla, said, "I am pleased to see the strong momentum in core therapies across our branded markets and sustained cost control leading to 10 per cent revenue growth and  22.2 per cent EBITDA margin for the quarter, offsetting price erosion and normalising covid contribution. In India, we continue to drive strong performance led by sustained volume traction despite a high FY21 base.  Our collaboration with Eli Lily for their diabetes products helps us further strengthen our endeavour of creating access to innovative medicines in line with the One-India strategy. The US business also witnessed a healthy run rate driven by core portfolio and desired traction in respiratory franchise across Albuterol and Arformoterol. International markets rebounded in line with expectations despite continuing  geopolitical challenges.